MiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer
EMBO Molecular Medicine · 11.01.2023 · 15 (1)
DOI: 10.15252/emmm.202216033 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, online erschienen am 25.11.2022. Verfasst von Roberto Dinami und 18 weiteren Autor:innen. Beteiligte Einrichtung: Translational Oncology Research Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. Hauptthemen laut MEDLINE: MicroRNAs, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute.
Abstract (Originalsprache)
The telomeric repeat‐binding factor 2 (TRF2) is a telomere‐capping protein that plays a key role in the maintenance of telomere structure and function. It is highly expressed in different cancer types, and it contributes to cancer progression. To date, anti‐cancer strategies to target TRF2 remain a challenge. Here, we developed a miRNA‐based approach to reduce TRF2 expression. By performing a high‐throughput luciferase screening of 54 candidate miRNAs, we identified miR‐182‐3p as a specific and efficient post‐transcriptional regulator of TRF2. Ectopic expression of miR‐182‐3p drastically reduced TRF2 protein levels in a panel of telomerase‐ or alternative lengthening of telomeres (ALT)‐positive cancer cell lines. Moreover, miR‐182‐3p induced DNA damage at telomeric and pericentromeric sites, eventually leading to strong apoptosis activation. We also observed that treatment with lipid nanoparticles (LNPs) containing miR‐182‐3p impaired tumor growth in triple‐negative breast cancer (TNBC) models, including patient‐derived tumor xenografts (PDTXs), without affecting mouse survival or tissue function. Finally, LNPs‐miR‐182‐3p were able to cross the blood–brain barrier and reduce intracranial tumors representing a possible therapeutic option for metastatic brain lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Oncology Research Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
- Department of Ecological and Biological Sciences (DEB), University of Tuscia, Viterbo, Italy.
- Department of Pharmacy, University Federico II of Naples, Naples, Italy.
- CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.
- Vall d'Hebron Institute of Oncology, Barcelona, Spain.
- Functional Genomics and RNA-based Therapeutics Laboratory, Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
ORCID-Profile: Roberto Dinami, Eleonora Petti, Manuela Porru, Angela Rizzo, Violeta Serra, Miguel Mano, Mauro Giacca, Madalena Tarsounas, Annamaria Biroccio
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- Ministero della Salute
Zitieren
APA
Dinami, R., Pompili, L., Petti, E., Porru, M., D'Angelo, C., Di Vito, S., Rizzo, A., Campani, V., De Rosa, G., Bruna, A., Serra, V., Mano, M., Giacca, M., Leonetti, C., Ciliberto, G., Tarsounas, M., Stoppacciaro, A., Schoeftner, S., & Biroccio, A. (2023). MiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer. EMBO Molecular Medicine, 15(1). https://doi.org/10.15252/emmm.202216033
Vancouver
Dinami R, Pompili L, Petti E, Porru M, D'Angelo C, Di Vito S, et al. MiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer. EMBO Molecular Medicine. 2023;15(1). doi:10.15252/emmm.202216033
BibTeX
@article{Dinami2023,
author = {Dinami, Roberto and Pompili, Luca and Petti, Eleonora and Porru, Manuela and D'Angelo, Carmen and Di Vito, Serena and Rizzo, Angela and Campani, Virginia and De Rosa, Giuseppe and Bruna, Alejandra and Serra, Violeta and Mano, Miguel and Giacca, Mauro and Leonetti, Carlo and Ciliberto, Gennaro and Tarsounas, Madalena and Stoppacciaro, Antonella and Schoeftner, Stefan and Biroccio, Annamaria},
title = {MiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer},
journal = {EMBO Molecular Medicine},
year = {2023},
volume = {15},
number = {1},
doi = {10.15252/emmm.202216033}
}
EUVIMED